|From: trendtn (Rep: 161)||Date: 02/21/2018 10:04|
|Forum: Cellectis SA - Msg #110||Thread #673992509 (Rec: 0) |
Not sure how much of this is new. A report on Chinese going full bore into crispr trials...without the same safety protocols demanded in the us.
They have 9 trials going on 9 fmdiferent types of cancers. The story highlights esophageal cancer...patients typically survive no more than six months. The Chinese say 40% have responded to the treatment...some for more than a year.
There is no publication of the data yet. The Chinese say there have been some patient deaths from the disease,not the treatment, which is to expected I suppose.
My general impression, this seems like an update on the WSJ story of a couple months go. Given the Chinese lack of safety caution I'm guardedly optimistic that crispr seems to be working in their trials. Makes me think it will succeed here as well.
Crispr stocks are clls, edit, ntla and crsp
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.